{
  "patient_id": "AK",
  "timestamp": "2026-01-11T04:27:02.136335",
  "pd_l1": {
    "status": "POSITIVE",
    "cps": 10,
    "eligible": true,
    "confidence": "HIGH",
    "evidence": "FDA approved: Pembrolizumab for PD-L1+ solid tumors (CPS \u2265 1)"
  },
  "msi": {
    "status_inferred": "MSS",
    "mmr_status": "PRESERVED",
    "mmr_proteins_intact": [
      "MLH1",
      "PMS2",
      "MSH2",
      "MSH6"
    ],
    "eligible": false,
    "confidence": "HIGH",
    "evidence": "FDA approved: Pembrolizumab for MSI-H/dMMR solid tumors"
  },
  "tmb": {
    "measured": null,
    "estimated": "LIKELY ELEVATED (>10 mut/Mb)",
    "mbd4_deficient": true,
    "eligible": true,
    "confidence": "MEDIUM",
    "evidence": "MBD4 homozygous pathogenic \u2192 BER deficiency \u2192 CpG\u2192TpG hypermutation \u2192 elevated TMB expected. Literature: PMID 30061086, 33508389."
  },
  "io_eligibility": {
    "eligible": true,
    "confidence": "HIGH",
    "primary_reason": "PD-L1 CPS \u2265 10",
    "qualifying_biomarkers": {
      "pd_l1": true,
      "msi_h": false,
      "tmb_h": true
    }
  },
  "drug_recommendations": [
    {
      "name": "Pembrolizumab",
      "brand": "Keytruda",
      "score": 0.85,
      "mechanism": "Anti-PD-1",
      "evidence": [
        "FDA approved for PD-L1+ solid tumors (CPS \u2265 1)",
        "KEYNOTE-158: TMB-H response rate 29%",
        "KEYNOTE-028/052: Ovarian cancer response 11.5%"
      ],
      "applicable_to_ayesha": [
        "PD-L1 CPS 10 (positive)",
        "Likely TMB-H (MBD4 deficiency)"
      ]
    },
    {
      "name": "Nivolumab",
      "brand": "Opdivo",
      "score": 0.82,
      "mechanism": "Anti-PD-1",
      "evidence": [
        "CheckMate-032: Ovarian cancer response",
        "Approved for MSI-H/dMMR cancers"
      ],
      "applicable_to_ayesha": [
        "PD-L1 positive",
        "Alternative to pembrolizumab"
      ]
    },
    {
      "name": "Dostarlimab",
      "brand": "Jemperli",
      "score": 0.78,
      "mechanism": "Anti-PD-1",
      "evidence": [
        "GARNET: dMMR/MSI-H solid tumors",
        "Endometrial/ovarian cancer focus"
      ],
      "applicable_to_ayesha": [
        "HGS-OC indication",
        "May have activity in PD-L1+"
      ]
    },
    {
      "name": "Atezolizumab",
      "brand": "Tecentriq",
      "score": 0.75,
      "mechanism": "Anti-PD-L1",
      "evidence": [
        "IMvigor: PD-L1+ cancers",
        "Different target (PD-L1 vs PD-1)"
      ],
      "applicable_to_ayesha": [
        "PD-L1 positive tumor"
      ]
    },
    {
      "name": "Pembrolizumab + Olaparib",
      "brand": "Keytruda + Lynparza",
      "score": 0.88,
      "mechanism": "Anti-PD-1 + PARP inhibitor",
      "evidence": [
        "MEDIOLA: DDR deficiency + IO synergy",
        "KEYLYNK-001: Ongoing ovarian trials"
      ],
      "applicable_to_ayesha": [
        "DDR deficiency (MBD4 + TP53)",
        "PD-L1 positive",
        "Potential synergy"
      ],
      "note": "COMBINATION - may be optimal for Ayesha"
    }
  ],
  "summary": {
    "io_eligible": true,
    "confidence": "HIGH",
    "top_recommendation": "Pembrolizumab",
    "combination_option": "Pembrolizumab + Olaparib",
    "next_steps": [
      "Confirm TMB with NGS panel",
      "Consider IO + PARP combination given DDR deficiency",
      "Discuss clinical trial options (ATHENA-COMBO, DUO-O)"
    ]
  }
}